Evidence map›Paper›PMID 36675988›Full record

ReviewLife (Basel, Switzerland)2022

Natural Product Co-Metabolism and the Microbiota-Gut-Brain Axis in Age-Related Diseases.

Mark Obrenovich, Sandeep Kumar Singh, Yi Li, George Perry, Bushra Siddiqui, Waqas Haq, V Prakash Reddy

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Pleiotropic attenuating effect ofChinese herbal medicines · 2024
    Article
  3. Pharmaceutics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mark ObrenovichResearch Service, Department of Veteran's Affairs Medical Center, Cleveland, OH 44106, USA.
Sandeep Kumar SinghIndian Scientific Education and Technology (ISET) Foundation, Lucknow 226002, India.ORCID 0000-0002-0022-6240
Yi LiDepartment of Nutrition and Dietetics, Saint Louis University, Saint Louis, MO 63103, USA.ORCID 0000-0002-5048-6075
George PerryDepartment of Neuroscience Developmental and Regenerative Biology, University of Texas, San Antonio, TX 78249, USA.ORCID 0000-0002-6547-0172
Bushra SiddiquiSchool of Medicine, Northeast Ohio College of Medicine, Rootstown, OH 44272, USA.
Waqas HaqSchool of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
V Prakash ReddyDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.ORCID 0000-0003-3011-4175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complementary alternative medicine approaches are growing treatments of diseases to standard medicine practice. Many of these concepts are being adopted into standard practice and orthomolecular medicine. Age-related diseases, in particular neurodegenerative disorders, are particularly difficult to treat and a cure is likely a distant expectation for many of them. Shifting attention from pharmaceuticals to phytoceuticals and "bugs as drugs" represents a paradigm shift and novel approaches to intervention and management of age-related diseases and downstream effects of aging. Although they have their own unique pathologies, a growing body of evidence suggests Alzheimer's disease (AD) and vascular dementia (VaD) share common pathology and features. Moreover, normal metabolic processes contribute to detrimental aging and age-related diseases such as AD. Recognizing the role that the cerebral and cardiovascular pathways play in AD and age-related diseases represents a common denominator in their pathobiology. Understanding how prosaic foods and medications are co-metabolized with the gut microbiota (GMB) would advance personalized medicine and represents a paradigm shift in our view of human physiology and biochemistry. Extending that advance to include a new physiology for the advanced age-related diseases would provide new treatment targets for mild cognitive impairment, dementia, and neurodegeneration and may speed up medical advancements for these particularly devastating and debilitating diseases. Here, we explore selected foods and their derivatives and suggest new dementia treatment approaches for age-related diseases that focus on reexamining the role of the GMB.

Indexed as

agingAlzheimer’s diseaseblood–brain barrierGinkgo bilobametabolic interactomemicrobiomemicrobiotamicrobiota–gut–brain axisnatural productsvascular dementia

Identifiers

PMID36675988
PMCPMC9865576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.